Activated Charcoal in Medical Applications

DAVID O. COONEY

University of Wyoming
Laramie, Wyoming
# CONTENTS

**Foreword**  
**Preface**

1 Introduction
   I. DATA ON POISONING INCIDENTS IN THE USA  
   II. INITIAL APPROACHES TO THE TREATMENT OF POISONING  
   III. THE GROWING USE OF ACTIVATED CHARCOAL  
   IV. GENERAL REVIEW PAPERS  
   V. REFERENCES

2 Historical Background of Activated Charcoal
   I. TERMINOLOGY  
   II. EARLY HISTORY  
   III. EVOLUTION OF METHODS FOR TESTING MEDICINAL CHARCOALS  
   IV. REFERENCES

3 Fundamentals of Activated Charcoal and the Adsorption Process
   I. THE MANUFACTURE OF ACTIVATED CHARCOAL  
      A. Carbonization  
      B. Activation with Oxidizing Gases  
   II. THE PROPERTIES OF ACTIVATED CHARCOAL  
      A. Densities  
      B. Pore Volume and Pore-Size Distribution  
      C. Surface Area  
      D. Nature of the Charcoal Surface  
   III. THE NATURE OF THE ADSORPTION PROCESS  
      A. Effect of Temperature  
      B. Nature of the Solvent  
      C. Surface Area of the Charcoal  
      D. Pore Structure of the Charcoal  
      E. Nature of the Solute  
      F. pH of the Solution  
      G. Presence of Inorganic Salts
<table>
<thead>
<tr>
<th>Section</th>
<th>Contents</th>
</tr>
</thead>
<tbody>
<tr>
<td>H. Competing Solutes</td>
<td>36</td>
</tr>
<tr>
<td>IV. DETERMINING ADSORPTION ISOTHERMS</td>
<td>37</td>
</tr>
<tr>
<td>A. The Langmuir Isotherm Equation</td>
<td>38</td>
</tr>
<tr>
<td>B. The Freundlich Isotherm Equation</td>
<td>41</td>
</tr>
<tr>
<td>C. Least-Squares Fitting of Data to Determine Isotherm Constants</td>
<td>43</td>
</tr>
<tr>
<td>D. Theoretical Aspects of Isotherm Equations</td>
<td>45</td>
</tr>
<tr>
<td>V. SUMMARY</td>
<td>46</td>
</tr>
<tr>
<td>VI. REFERENCES</td>
<td>47</td>
</tr>
</tbody>
</table>

4 Properties of Antidotal Charcoal

| I. REQUIREMENTS OF THE U. S. PHARMACOPEIA | 50 |
| II. "SUPERACTIVE" CHARCOAL | 53 |
| III. CURRENTLY AVAILABLE USP CHARCOALS IN THE USA | 55 |
| IV. CURRENTLY AVAILABLE CHARCOAL PRODUCTS IN THE USA | 56 |
| V. OTHER CURRENTLY AVAILABLE CHARCOAL PRODUCTS | 61 |
| VI. THE "CONTAINER RESIDUE" ISSUE | 64 |
| VII. COMPARATIVE STUDIES OF ANTIDOTAL CHARCOALS | 66 |
| VIII. SUMMARY | 70 |
| IX. REFERENCES | 71 |

5 The Nature of Drug Absorption, Distribution, and Elimination

| I. THE EFFECT OF DRUG DOSAGE FORM | 73 |
| II. ROUTES OF DRUG ADMINISTRATION | 75 |
| III. THE ROLE OF pH IN DRUG ABSORPTION | 75 |
| IV. MECHANICAL ASPECTS OF GASTROINTESTINAL PHYSIOLOGY | 77 |
| V. ABSORPTION IN THE GASTROINTESTINAL TRACT | 79 |
| VI. DRUG FATE AFTER ABSORPTION | 82 |
| VII. GASTROINTESTINAL DIALYSIS AND INTERRUPTION OF THE ENTEROHEPATIC CYCLE | 85 |
| VIII. SUMMARY | 88 |
| IX. REFERENCES | 89 |

6 Basic Details of Pharmacokinetic Modeling

| I. INTRODUCTION | 91 |
| II. THE PHARMACOKINETICS OF INTRAVENOUSLY ADMINISTERED DRUGS | 96 |
| A. The One Compartment Open Model | 98 |
| B. The Two Compartment Open Model | 103 |
| III. MODELS WITH FIRST-ORDER DRUG ABSORPTION | 105 |
| A. One Compartment Open Model | 105 |
| B. Two Compartment Open Model | 106 |
| IV. EXAMPLES OF PHARMACOKINETIC CALCULATIONS | 106 |
| A. Area Under the Curve | 107 |
| B. Elimination Half-life | 107 |
| C. Estimating $t_{1/2}$ for Drug Absorption | 107 |
| D. Mean Residence Time | 107 |
| V. SUMMARY | 108 |
| VI. REFERENCES | 108 |

7 Methods for Treating Poisoning and Drug Overdose

| I. GENERAL CHARACTERISTICS OF POISONED PATIENTS | 110 |
## Contents

II. GENERAL OVERDOSE MANAGEMENT STRATEGIES 110  
   A. Oral Dilution 113  
   IV. INDUCED EMESIS WITH SYRUP OF IPECAC 115  
      A. Toxicity of Ipecac 118  
      B. Other Adverse Effects of Ipecac 120  
      C. Success of Ipecac in Producing Emesis 120  
      D. Comparison of Ipecac and Apomorphine in Producing Emesis 123  
      E. Effectiveness of Ipecac and Apomorphine in Recovering Stomach Contents 124  
      F. General Comments on the Use of Ipecac 126  

V. GASTRIC LAVAGE 127  
VI. COMPARISON OF IPECAC AND LAVAGE 130  
VII. USE OF SALINE CATHARTICS OR SORBITOL 135  
VIII. WHOLE-BOWEL IRRIGATION 138  
IX. ALTERING DIURETIC PROCESSES 140  
X. EXCHANGE TRANSFUSION 142  
XI. HEMODIALYSIS AND HEMOPERFUSION 142  
XII. SUMMARY 147  
XIII. REFERENCES 149

8 The Design of Clinical Studies and Data Treatment 157  
   I. RANDOMIZED CROSS-OVER AND OTHER TYPES OF STUDIES 157  
   II. ASSESSMENT OF THE STATISTICAL SIGNIFICANCE OF DIFFERENCES IN TREATMENTS 159

9 Some Basic Aspects of Antidotal Charcoal 163  
   I. CHARCOAL POWDER VERSUS TABLETED CHARCOAL 163  
   II. OPTIMAL DOSE OF ACTIVATED CHARCOAL 166  
   III. STABILITY OF THE DRUG/CHARCOAL COMPLEX 168  
   IV. STORAGE STABILITY OF CHARCOAL SUSPENSIONS 174  
   V. UNIVERSAL ANTIDOTE 175  
   VI. EFFECT OF PEPSIN ON IN VITRO ADSORPTION 179  
   VII. SUMMARY 180  
   VIII. REFERENCES 182

10 The Classic Studies of Andersen 185  
   I. ANDERSEN'S IN VITRO ADSORPTION STUDIES 185  
   II. THE EFFECT OF pH 187  
   III. ADSORPTION FROM GASTROINTESTINAL CONTENTS 189  
   IV. FURTHER IN VIVO EXPERIMENTS 195  
   V. REFERENCES 195

11 Effects of Activated Charcoal on Major Classes of Drugs and Chemicals 197  
   I. COMMON HOUSEHOLD CHEMICALS 198  
   II. ALKALOIDS 198  
   III. ASPIRIN AND OTHER SALICYLATES 201  
      A. In Vitro Studies 201  
      B. In Vivo Studies 201  
   IV. ACETAMINOPHEN AND INTERACTIONS WITH ACETYLCYSTEINE 204  
      A. In Vitro Studies 205  
      B. In Vivo Studies 205
C. Interactions with N-acetylcysteine  209

V. HYPNOTICS AND SEDATIVES  214
A. In Vitro Studies  214
B. In Vivo Studies  216

VI. TRICYCLIC ANTIDEPRESSANTS  220
A. Other In Vitro Studies  221
B. In Vivo Studies  222

VII. CARDIAC GLYCOSIDES  226

VIII. ORGANIC SOLVENTS  230

IX. ETHANOL  235

X. SUMMARY  238

XI. REFERENCES  239

12 Effect of Charcoal on Other Classes of Drugs  245

I. ANTIHISTAMINES  247
A. Chlorpheniramine  247
B. Diphenhydramine  250

II. ANTI-INFECTIVES  250
A. Antibiotics  250
B. Antituberculosis Agents  251
C. Antimalarial Agents  253
D. Quinolones: Ciprofloxacin  256
E. Sulfones: Dapsone  256
F. Urinary Anti-Infectives: Trimethoprim  257

III. CARDIAC DRUGS  257
A. Anti-Arrhythmics  257
B. Beta-Blockers  262
C. Calcium Channel-Blockers: Diltiazem  262

IV. CNS AGENTS  263
A. Analgesics  263
B. Anticonvulsants  267
C. Anti-Inflammatory Agents  270
D. Tranquilizers  271
E. Other CNS Agents: Methamphetamine  274

V. GASTROINTESTINAL DRUGS  275
A. Cimetidine  275
B. Propantheline  275
C. Diphenoxylate  275
D. Nizatidine  275

VI. ANTIDIABETIC SULFONYLUREAS  276

VII. RESPIRATORY RELAXANTS: THEOPHYLLINE  277
A. In Vitro Studies  278
B. Animal Studies  278
C. Human Volunteer Studies  278
D. Human Overdose Studies  280
E. Conclusions About Theophylline  281

VIII. ORGANIC SUBSTANCES  281
A. Camphor  281
B. Ethylene Glycol  281
C. Isopropanol and Acetone  281
D. Polybrominated Biphenyl  282
E. Herbicides  282
13 Effect of Administration Time, Food, and Gastric pH

I. EFFECT OF A DELAY IN ADMINISTRATION
   A. Aspirin and Other Salicylates
   B. Acetaminophen
   C. Barbiturates
   D. Tricyclic Antidepressants
   E. Cardiac Glycosides
   F. Theophylline
   G. Propoxyphene
   H. Other Drugs

II. EFFECT OF FOOD

III. EFFECT OF GASTRIC pH

IV. SUMMARY

V. REFERENCES

14 Effect of Multiple Doses of Charcoal

I. ASPIRIN

II. ACETAMINOPHEN

III. PHENOBARBITAL

IV. DIGOXIN AND DIGITOXIN
   A. Human Volunteer Studies with Subtoxic Doses
   B. Overdose Case Reports

V. TRICYCLIC ANTIDEPRESSANTS
   A. Human Volunteer Studies with Subtoxic Doses
   B. Overdose Case Reports

VI. THEOPHYLLINE
   A. Animal Studies
   B. Human Volunteer Studies with Subtoxic Oral Doses
   C. Human Volunteer Studies with Subtoxic IV Doses
   D. Human Overdose Case Reports

VII. QUININE

VIII. ANTIBIOTICS

IX. PROPOXYPHENE

X. DAPSONE

XI. CARBAMAZEPINE

XII. PHENYTOIN
   A. Human Studies with Subtoxic IV Doses
   B. Human Overdose Reports
XIII. PIROXICAM 341
XIV. OTHER DRUGS 341
A. Glutethimide and Barbital 341
B. Phenobarbital and Diazepam 341
C. Meprobamate 342
D. Diltiazem 342
E. Nadolol and Sotalol 342
F. Chlorpropamide 343
G. Cyclosporin 343
H. Phencyclidine 343
I. Paroxetine 343
J. Disopyramide 344
K. Methotrexate 344
XV. LIMITATIONS ON MULTIPLE-DOSE CHARCOAL THERAPY 344
XVI. SUMMARY 345
XVII. REFERENCES 350

15 Ipecac, Cathartics, and Charcoal: Interactions and Comparative Efficacies 357
I. EFFECT OF CHARCOAL ON IPECAC 357
II. COMPARATIVE EFFECTIVENESS OF IPECAC AND CHARCOAL 359
III. COMPARATIVE EFFECTIVENESS OF LAVAGE AND CHARCOAL 365
IV. COMPARATIVE EFFECTIVENESS OF WHOLE BOWEL IRRIGATION AND CHARCOAL 367
V. EFFECTS OF SORBITOL ON THE ACTION OF CHARCOAL 371
A. Some Preliminary Comments 372
B. Effects of Sorbitol on GI Transit Times 373
C. Dosage Recommendations for Sorbitol 374
D. Effect of Sorbitol on the Efficacy of Charcoal 375
E. Conclusions and Recommendations 382
VI. EFFECT OF SALINE CATHARTICS ON THE ACTION OF CHARCOAL 383
A. In Vitro Studies 383
B. In Vivo Studies 387
C. Summary and Conclusions 391
VII. SUMMARY 391
VIII. REFERENCES 392

16 The Development Of Palatable Formulations 397
I. PROVIDING LUBRICITY 398
II. PROVIDING FLAVOR 402
III. OTHER APPROACHES TO PALATABILITY 414
IV. SUMMARY 414
V. REFERENCES 415

17 Hazards Associated with Antidotal Charcoal Use 418
I. GENERAL TOXICITY OF CHARCOAL 418
II. ASPIRATION 419
III. PERFORATIONS 423
IV. BRONCHIOLITUS OBLITERANS 424
V. EMPYEMA 424
Contents

VI. INFECTIONS IN THE RESPIRATORY TRACT FROM NONSTERILE CHARCOAL 425
VII. ABDOMINAL DISTENSION FROM SORBITOL 425
VIII. HYPERNATREMIA AND HYPERMAGNESEMIA 426
IX. CONSTIPATING EFFECT OF CHARCOAL 431
X. OBSTRUCTIONS CAUSED BY CHARCOAL 432
XI. RECTAL ULCER WITH HEMORRHAGE 434
XII. CORNEAL ABRASIONS 434
XIII. "BLACK SMOKE SYNDROME" 435
XIV. SUMMARY 435
XV. REFERENCES 436

18 Effect of Charcoal on Various Inorganic Substances 439

I. ARSENIC 440
II. BORIC ACID 440
III. CESIUM 441
IV. IRON 441
V. LITHIUM 442
VI. PHOSPHORUS 442
VII. POTASSIUM 443
VIII. CYANIDE 443
IX. THALLIUM 444
X. SUMMARY 444
XI. REFERENCES 444

19 Effect of Charcoal on Endogenous Biochemicals 446

I. BILE SALTS 446
II. BILIRUBIN 447
III. EFFECT ON PRURITUS 450
IV. EFFECT ON ERYTHROPOIETIC PORPHYRIA 451
V. EFFECT ON UREMIC TOXINS 454
VI. HYPOLIPIDEMIC EFFECTS OF CHARCOAL 456
VII. EFFECTS IN LIVER DISEASE 460
VIII. PROLONGATION OF ANIMAL LIFESPAN 461
IX. SUMMARY 462
X. REFERENCES 463

20 Use of Charcoal to Treat Poisoning in Animals 467

I. INCIDENCE OF ANIMAL POISONING AND GENERAL GUIDELINES FOR CHARCOAL USE 467
II. VETERINARY ACTIVATED CHARCOAL PRODUCTS 468
III. COMMON SOURCES OF ANIMAL POISONS AND TOXINS 469
IV. POISONING BY PLANTS 470
V. POISONING DUE TO HERBICIDES, PESTICIDES, AND INSECTICIDES 472
VI. FUNGAL TOXINS FROM GRAINS 478
VII. TOXINS FROM ALGAE 481
VIII. OTHER TOXINS 481
IX. POISONING OF HOUSEHOLD PETS 482
X. SUMMARY 483
XI. REFERENCES 483
21 Reports from the Soviet Union

I. INTRODUCTION
II. ENTEROSORPTION STUDIES DESCRIBED BY NIKOLAEV
III. SOME OTHER STUDIES
IV. REFERENCES

22 Resins and Clays as Sorbents

I. BASIC TYPES AND PROPERTIES OF RESINS USED AS ANTIDOTES
II. BASIC TYPES AND PROPERTIES OF CLAYS
III. STUDIES INVOLVING CLAYS
IV. STUDIES INVOLVING RESINS
   A. General Studies of Ion Exchange Resins
   B. General Studies of Cholestyramine and Colestipol
   C. Effects of Cholestyramine and Colestipol in Cardiac Glycoside Overdoses
   D. Effects of Cholestyramine and Colestipol on Other Drugs
   E. Effects of Cholestyramine and Colestipol on Concomitant Drugs Taken Therapeutically
   F. Effects of Resins on Various Endogenous Biochemicals
   G. Use of Cholestyramine for Treating Hydrocarbon Toxicity
   H. Effect of Cholestyramine and Colestipol on Bacterial Toxins and Antibiotics
   I. Effect of Sodium Polystyrene Sulfonate on Inorganic Species
V. SUMMARY
VI. REFERENCES

23 Other Medicinal Uses of Charcoal in Humans

I. EFFECT OF CHARCOAL ON SURFACE WOUNDS
II. EFFECT OF CHARCOAL ON VARIOUS SKIN PROBLEMS
III. EFFECT ON GI TRACT BACTERIAL SEPSIS
IV. EFFECT ON INTESTINAL GAS
V. EFFECT ON DIARRHEA
VI. EFFECT ON PEPTIC ULCERS
VII. USE IN DEODORIZING OSTOMIES
VIII. USE IN THE TREATMENT OF ALCOHOLISM
IX. CHARCOAL AS A VEHICLE FOR PROLONGED-RELEASE MEDICATIONS
X. CHARCOAL INJECTED INTRAVENOUSLY
XI. SUMMARY
XII. REFERENCES

24 Other Biochemical and Biological Uses of Charcoal

I. SNAKE VENOM ADSORPTION
II. VIRUS ADSORPTION
III. BIOCHEMICAL FACTOR ADSORPTION
IV. BACTERIA ADSORPTION
V. BACTERIAL TOXIN ADSORPTION
VI. FUNGAL TOXIN ADSORPTION
VII. ADSORPTION OF ENZYMES AND OTHER PROTEINS
VIII. HORMONE ADSORPTION
IX. VITAMIN ADSORPTION
Contents

X. ADSORPTION OF WHISKEY CONGENERS 549
XI. CATALYSIS OF REACTIONS BY ACTIVATED CHARCOAL 550
XII. MISCELLANEOUS COMPOUNDS ADSORBED BY CHARCOAL 551
XIII. CHARCOAL USE IN CONCENTRATING DRUGS FROM BIOLOGICAL FLUIDS 551
XIV. USE OF CHARCOAL IN THE ASSAY OF BIOCHEMICALS 552
XV. PROTECTION OF CROP PLANT SEEDLINGS FROM HERBICIDE DAMAGE 554
XVI. EFFECT OF CHARCOAL ON PLANT TISSUE CULTURES 558
XVII. EFFECT OF CHARCOAL ON BACTERIAL CULTURES 559
XVIII. EFFECTS OF CHARCOAL ON INSECTS 562
XIX. SUMMARY 563
XX. REFERENCES 564

25 Summary 571

I. POSITIVE ASPECTS OF ACTIVATED CHARCOAL 571
II. SOME NEGATIVE ASPECTS OF ACTIVATED CHARCOAL 572
III. UNSETTLED ISSUES 573
IV. RECOMMENDATIONS 574
V. REFERENCES 575

Index 577